Candel Therapeutics (CADL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Voting matters and shareholder proposals
Election of four Class II directors: Edward J. Benz, Jr., Paul B. Manning, Maha Radhakrishnan, and Paul Peter Tak, with board recommending a vote in favor.
Ratification of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, recommended by the board.
Additional business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends all four nominees for Class II director positions.
Audit committee and external auditor matters
Proposal to ratify KPMG LLP as the external auditor for the 2026 fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Candel Therapeutics
- Lead viral immunotherapies deliver strong efficacy in solid tumors, with pivotal trials and filings ahead.CADL
Jefferies Global Healthcare Conference 20263 Jun 2026 - Aglatimagene plus radiotherapy improved disease-free survival by 39% and reduced recurrence risk.CADL
Study result22 May 2026 - Aglatimagene achieved significant disease-free survival in prostate cancer, with BLA filing on track.CADL
Stifel 2026 Targeted Oncology Virtual Forum20 May 2026 - Aglatimagene and linoserpaturev show strong efficacy and safety across multiple cancer indications.CADL
Corporate presentation14 May 2026 - Lead programs show strong efficacy and safety across major cancers, with broad market potential.CADL
Corporate presentation14 May 2026 - Net loss of $8.9M in Q1 2026; BLA submission and launch prep for aglatimagene advance.CADL
Q1 202614 May 2026 - Virtual meeting to elect directors, ratify auditor, and review governance and compensation.CADL
Proxy filing29 Apr 2026 - Aglatimagene and linoserpaturev show strong efficacy and safety across multiple cancer types.CADL
Corporate presentation16 Apr 2026 - Lead programs show strong efficacy and safety in major cancers, with broad commercial potential.CADL
Corporate presentation23 Mar 2026